EU/3/15/1497 - orphan designation for treatment of Huntington’s disease
5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride
OrphanHuman
Overview
On 21 May 2015, orphan designation (EU/3/15/1497) was granted by the European Commission to Prana Biotechnology UK Limited, United Kingdom, for 5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride for the treatment of Huntington's disease.
The sponsorship was transferred to Drug Development and Regulation S.L., Spain, in April 2019.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in November 2019 on request of the Sponsor.
Huntington's disease is a hereditary disease that causes brain cells to die, leading to symptoms such as involuntary jerky movements, behavioural problems and dementia (loss of intellectual function). The disease is usually first noticed between 35 and 45 years of age and gets worse over time.
Huntington's disease is caused by defects in the gene responsible for the production of a protein called huntingtin. The gene abnormalities result in an abnormal form of the protein being produced, which causes damage to the cells in specific areas of the brain.
Huntington's disease is a debilitating and life-threatening condition because it causes severe behavioural and mental problems, a progressive loss of the ability to move and potentially life-threatening complications.
At the time of designation, Huntington's disease affected approximately 1 in 10,000 people in the European Union (EU). This was equivalent to a total of around 51,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 512,900,000 (Eurostat 2015).
At the time of designation, the treatments authorised in the EU for Huntington's disease were aimed at relieving the symptoms of the disease. In some Member States, haloperidol, pimozide, tetrabenazine and tiapride were authorised for the abnormal involuntary movements that occur in Huntington's disease. In addition, benzodiazepines were used for anxiety, and antidepressants and lithium to treat depression and mood swings.
The sponsor has provided sufficient information to show that this medicine might be of significant benefit for patients with Huntington's disease because early studies showed an improvement in the outcome of patients when the medicine was used in combination with tetrabenazine. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.
In Huntington's disease, the abnormal huntingtin proteins stick together (aggregate) and damage brain cells. It is thought that the formation of huntingtin aggregates is linked to the accumulation of metals such as copper inside cells. This medicine is expected to attach to copper inside cells, thereby reducing the aggregation of the abnormal huntingtin proteins and the associated damage to brain cells.
The effects of the medicine have been evaluated in experimental models.
At the time of submission of the application for orphan designation, a clinical trial with the medicine in patients with Huntington's disease had been completed and further studies were planned.
At the time of submission, the medicine was not authorised anywhere in the EU for Huntington's disease. Orphan designation of the medicine had been granted in the United States for this condition.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 16 April 2015 recommending the granting of this designation.
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
Key facts
- Active substance
- 5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride
- Intended use
- Treatment of Huntington’s disease
- Orphan designation status
- Withdrawn
- EU designation number
- EU/3/15/1497
- Date of designation
- Sponsor
Drug Development and Regulation S.L.
Consell de Cent 375
Piso 03 01
Barcelona
Spain
Tel. +34 9352 85385
E-mail: info@ddrmedic.com
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
EMA list of opinions on orphan medicinal product designation
EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: